Immediate Impact
66 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Liquid biopsy in cancer: current status, challenges and future prospects
2024 Standout
Works of I. Toledano being referenced
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| I. Toledano | 133 | 25 | 72 | 121 | 91 | 16 | 268 | |
| Tosol Yu | 97 | 40 | 136 | 68 | 66 | 19 | 318 | |
| Alice Mège | 95 | 44 | 69 | 90 | 69 | 17 | 270 | |
| Giuseppe Giovinazzo | 92 | 103 | 90 | 75 | 127 | 14 | 319 | |
| Nachi Palaniappan | 85 | 32 | 68 | 204 | 161 | 16 | 296 | |
| Camilla Delli Paoli | 109 | 48 | 134 | 42 | 50 | 22 | 277 | |
| Zhining Yang | 72 | 94 | 99 | 105 | 93 | 20 | 305 | |
| Jan‐Olof Fernberg | 178 | 11 | 106 | 60 | 98 | 11 | 305 | |
| Minh Thi Tieu | 48 | 117 | 85 | 58 | 57 | 16 | 331 | |
| B. Dessard-Diana | 94 | 33 | 88 | 139 | 171 | 19 | 290 | |
| Douglas Klotch | 85 | 22 | 132 | 148 | 151 | 17 | 323 |
All Works
Loading papers...